COVID-KOSHA
Home
Help
(current)
Comment
!
Note: Language translations may be imperfect
A model anti-pandemic portal for scientists & public
High priority articles (R1, Most articles most likely to be relevant):
Second priority articles (R2, Moderate portion of articles likely to be relevant):
Other articles (R3, Lesser portion of articles likely to be relevant):
Molecular Interactions
Last updated: 2024 Nov 18
Total hit(s): 5652
S.No.
PMID
Ascending order
Descending order
Title
Ascending order
Descending order
Journal Name
Ascending order
Descending order
Publish Date
Ascending order
Descending order
Impact Factor
Ascending order
Descending order
Citations
Ascending order
Descending order
Auto summary
Ascending order
Descending order
1
39397784
A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity.
Hum Vaccin Immunother
2024 Dec 31
4.7
1
2
38512394
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults.
Hum Vaccin Immunother
2024 Dec 31
4.7
1
3
38361363
Serological assessment of the durability of vaccine-mediated protection against SARS-CoV-2 infection.
Hum Vaccin Immunother
2024 Dec 31
4.7
1
4
39489230
Structural basis of the C-terminal domain of SARS-CoV-2 N protein in complex with GMP reveals critical residues for RNA interaction.
Bioorg Med Chem Lett
2024 Dec 1
4.9
1
5
38860446
The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.
Emerg Microbes Infect
2024 Dec
5.84
1
6
38304547
Binding affinity between coronavirus spike protein and human ACE2 receptor.
Comput Struct Biotechnol J
2024 Dec
5.11
1
7
39027652
CORACLE (COVID-19 liteRAture CompiLEr): A platform for efficient tracking and extraction of SARS-CoV-2 and COVID-19 literature, with examples from post-COVID with respiratory involvement.
Comput Struct Biotechnol J
2024 Dec
5.11
1
8
39226846
Eugenol's electrochemical behavior, complexation interaction with copper chloride, antioxidant activity, and potential drug molecular docking application for Covid-19.
Colloids Surf B Biointerfaces
2024 Dec
1
9
39188530
Structure of SARS-CoV-2 MTase nsp14 with the inhibitor STM957 reveals inhibition mechanism that is shared with a poxviral MTase VP39.
J Struct Biol X
2024 Dec
1
10
39502345
Bronchial Artery Embolization for Life-Threatening Hemoptysis in COVID-19 Patients.
Int J Angiol
2024 Dec
1
11
38717195
Humoral responses to multiple SARS-CoV-2 variants after two doses of vaccine in kidney transplant patients.
Virulence
2024 Dec
4.81
1
12
39259045
Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages.
Emerg Microbes Infect
2024 Dec
5.84
1
13
39087555
Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium.
Emerg Microbes Infect
2024 Dec
5.84
1
14
38953857
A novel bispecific antibody targeting two overlapping epitopes in RBD improves neutralizing potency and breadth against SARS-CoV-2.
Emerg Microbes Infect
2024 Dec
5.84
1
15
39541975
The ALS drug riluzole binds to the C-terminal domain of SARS-CoV-2 nucleocapsid protein and has antiviral activity.
Structure
2024 Nov 8
9.2
1
16
39510125
Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1.
Nature
2024 Nov 7
24.36
3
17
39506608
A Novel Cell- and Virus-Free SARS-CoV-2 Neutralizing Antibody ELISA Based on Site-Specific Labeling Technology.
Anal Chem
2024 Nov 7
6.37
2
18
39501289
A novel neutralizing monoclonal antibody recognizes a linear antigenic epitope of the spike protein of swine acute diarrhoea syndrome coronavirus.
Virol J
2024 Nov 6
2.45
1
19
39506849
SARS-CoV-2 nucleocapsid protein interaction with YBX1 displays oncolytic properties through PKM mRNA destabilization.
Mol Cancer
2024 Nov 6
11.35
1
20
39500906
A protein vaccine of RBD integrated with immune evasion mutation shows broad protection against SARS-CoV-2.
Signal Transduct Target Ther
2024 Nov 6
- n/a -
1
21
39504352
Monoclonal antibodies against the spike protein alter the endogenous humoral response to SARS-CoV-2 vaccination and infection.
Sci Transl Med
2024 Nov 6
11.64
1
22
39504245
Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination.
Cell Rep
2024 Nov 5
7.7
1
23
39494911
A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation.
J Virol
2024 Nov 4
4.16
1
24
39531907
Exploring B-cell epitope conservation and antigenicity shift in current COVID-19 variants: Analyzing spike-antibody interactions for therapeutic uses.
Biochem Biophys Res Commun
2024 Nov 4
2.73
1
25
39497098
Immunopathological markers and cell types linked to COVID-19 symptom manifestation.
BMC Infect Dis
2024 Nov 4
2.58
1